Accenture plc (ACN - Free Report) recently secured an order from Trinity Health for its Unified Clinical Organization (UCO) model designed to improve care co-ordination and patient outcomes..
In accordance with the agreement, Accenture provided a standardized platform to increase the efficiency in Trinity’s IT system, advancing its clinical and disease management processes across 49 Trinity hospitals.
This has enhanced the modern life saving process, as it has resulted in an 18.0% reduction in mortality rates, saving a total of 400 lives due to proactive management.
Competition is close on its heels, however, with tech behemoths like IBM (IBM - Free Report) and Dell Inc. (DELL), as well as a host of smaller players looking for a share of the healthcare market. Given the size and growth prospects of the healthcare market and the scope for technology purchases in the segment, Accenture should be able to carve out its own niche.
Over the last decade, Accenture has successfully won many deals across different verticles. However, we believe that it is time for the company to focus on deals with higher margins. A series of contract wins at the beginning of 2013 is certainly a good start for Accenture.
Although cloud-based solutions provided by Accenture seem to be in demand for companies across the world, post implementation challenges faced by different companies may be a cause of concern for this leading global IT company. This may have an impact on the real-time client output and efficiency. At times, companies incur financial and business losses for not having a customized cloud solution.
Currently, Accenture has a Zacks Rank #3 (Hold). Investors may also look into other technology stocks, which are better positioned such as Corelogic Inc. (CLGX - Free Report) with a Zacks Rank #1 (Strong Buy) and Computer Sciences Corp. (CSC - Free Report) with a Zacks Rank #2 (Buy).